Related Experiment Video

Updated: May 22, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

The mTOR pathway in lung cancer and implications for therapy and biomarker analysis

Simon Ekman1, Murry W Wynes, Fred R Hirsch

  • 1Division of Medical Oncology and Pathology, University of Colorado Denver, Aurora, CO 80045, USA.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|May 17, 2012
PubMed

Insights

Targeting the mammalian target of rapamycin (mTOR) pathway offers a promising therapeutic strategy for lung cancer. This review details mTOR signaling, its role in cancer, and clinical trials for non-small cell and small cell lung cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Mammalian target of rapamycin (mTOR) is a critical kinase regulating cell growth, metabolism, and angiogenesis.
  • Dysregulation of mTOR signaling is a common hallmark in various cancers, including lung cancer.
  • Targeting mTOR presents a viable therapeutic avenue for lung cancer treatment.

Purpose of the Study:

  • To review the mTOR signaling pathway in the context of lung cancer.
  • To identify therapeutic intervention points and biomarker strategies within the mTOR pathway.
  • To summarize current clinical trials investigating mTOR inhibitors in lung cancer.

Main Methods:

  • Literature review of scientific publications and clinical trial data.
  • Analysis of the mTOR signaling pathway's role in oncogenesis.
  • Synthesis of information on therapeutic targeting and biomarker development.

Main Results:

  • The mTOR pathway is frequently dysregulated in lung malignancies.
  • Specific mTOR pathway components offer targets for novel lung cancer therapies.
  • Biomarker analysis can guide patient selection for mTOR-targeted treatments.

Conclusions:

  • Targeting the mTOR pathway is a significant strategy for developing new lung cancer therapeutics.
  • Further research and clinical trials are essential to optimize mTOR-targeted therapies for both non-small cell and small cell lung cancer.
  • Biomarker-driven approaches will be crucial for personalized treatment strategies.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...